Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd (PPBT) is a clinical-stage oncology innovator developing therapies to combat tumor resistance mechanisms. This hub provides investors and researchers with timely updates on the company’s pipeline progress, including its dual inhibitor NT219, CEACAM1-targeting CM24 antibody, and tri-specific antibody platform.
Key resources include: Press releases detailing clinical trial milestones for lead candidates, partnership announcements with pharmaceutical collaborators, and regulatory filings related to drug development. Users will find analysis of preclinical data alongside updates on combination therapy strategies involving immunotherapies.
Bookmark this page to efficiently track PPBT’s advancements in overcoming immune evasion through novel mechanisms like STAT3 inhibition and localized immune activation. Check regularly for new insights into trial designs, biomarker analyses, and strategic initiatives shaping the future of precision oncology.
Purple Biotech announced interim data from its Phase 2 study of CM24 in combination with nivolumab and standard-of-care (SoC) chemotherapy for second-line metastatic pancreatic cancer (PDAC) at ASCO 2024.
The results show a 26% reduction in the risk of death and a 28% reduction in risk of progression or death. Patients treated with CM24+nivolumab+SoC had a median overall survival of 7.72 months compared to 5.62 months with SoC alone.
Additionally, the combination therapy resulted in a 1.9-month improvement in median progression-free survival. The objective response rate (ORR) and disease control rate (DCR) were also higher in the experimental arm (25% and 63%, respectively) compared to SoC (7% and 40%).
The study enrolled 63 patients across 18 centers in the U.S., Spain, and Israel. The investigational therapy was well-tolerated with manageable side effects. Topline final data is expected by the end of 2024.
Purple Biotech announced its Q1 2024 financial results. Key highlights include interim Phase 2 data for CM24 in pancreatic cancer to be presented at ASCO 2024, suggesting a reduced risk of disease progression and death. Topline data expected in Q4 2024. Positive efficacy data for NT219 in head and neck cancer were presented at ESMO-TAT 2024, with a Phase 2 trial planned for 2024. The company reported a net loss of $3.8 million, down from $4.9 million in Q1 2023, and operating losses decreased to $4.5 million. Purple Biotech's cash position stands at $10.8 million, providing a runway into Q1 2025. Sales, general, and administrative expenses decreased by 37.5% to $1 million.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
